ERNA (Ernexa Therapeutics) Float Percentage Of Total Shares Outstanding : 65.72% (As of May. 06, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Ernexa Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ernexa Therapeutics's float shares is 40.86 Mil. Ernexa Therapeutics's total shares outstanding is 62.18 Mil. Ernexa Therapeutics's float percentage of total shares outstanding is 65.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ernexa Therapeutics's Insider Ownership is 34.93%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ernexa Therapeutics's Institutional Ownership is 1.96%.

Ernexa Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ernexa Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	40.86	/	62.18
	=	65.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ernexa Therapeutics Inc (NAS:ERNA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.ernexatx.com

Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Executives

Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536